High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non‐squamous non‐small‐cell lung cancer

摘要: Background Epidermal growth factor receptor (EGFR) mutation positivity in primary non-small-cell lung cancer (NSCLC) may confer increased sensitivity to EGFR tyrosine kinase inhibitor (TKI) therapy with improved progression-free survival over wild-type tumours. Some subtypes not such TKI sensitivity. The incidence of rare and compound the Australian population is fully defined. Aims The aim study was audit serial cases non-squamous NSCLC presenting two multidisciplinary team meetings metropolitan Sydney for incidence, type phenotypic association positivity. Methods Serially were tested mutation. presented either referred testing on basis histopathology. Samples from sites analysed at one three different laboratories, each using a slightly assay. Data characteristics, smoking history clinicopathological features tumour collected. Results There relatively high series patients drawn rate 23.8%. A proportion mutations identified (6/32 positive cases, 18.8%). Conclusions The be higher populations than other predominantly European origin. Rare occur have implications treatment that differ classically activating mutations.